Page last updated: 2024-11-04

vorinostat and Adenocystic Carcinoma

vorinostat has been researched along with Adenocystic Carcinoma in 1 studies

Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).

Research Excerpts

ExcerptRelevanceReference
"Vorinostat is a histone deacetylase inhibitor (HDACi)."2.84A phase 2 study of vorinostat in locally advanced, recurrent, or metastatic adenoid cystic carcinoma. ( Barrett, MT; Boerner, SA; Casetta, L; Chao, J; Chen, A; Goncalves, PH; Hansen, AR; Heilbrun, LK; Kummar, S; Lenkiewicz, E; LoRusso, PM; Malasi, S; Piekarz, RL; Pilat, MJ; Siu, LL; Smith, DW; Sukari, AW, 2017)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Goncalves, PH1
Heilbrun, LK1
Barrett, MT1
Kummar, S1
Hansen, AR1
Siu, LL1
Piekarz, RL1
Sukari, AW1
Chao, J1
Pilat, MJ1
Smith, DW1
Casetta, L1
Boerner, SA1
Chen, A1
Lenkiewicz, E1
Malasi, S1
LoRusso, PM1

Trials

1 trial available for vorinostat and Adenocystic Carcinoma

ArticleYear
A phase 2 study of vorinostat in locally advanced, recurrent, or metastatic adenoid cystic carcinoma.
    Oncotarget, 2017, May-16, Volume: 8, Issue:20

    Topics: Adult; Aged; Carcinoma, Adenoid Cystic; Chromatin Assembly and Disassembly; Exome Sequencing; Female

2017